Hydroxycarbamide (HC), also known as hydroxyurea, is a successful, long-term therapy for sickle cell disease (SCD) and was, until very recently, the only US Food and Drug Administration (FDA) approved drug for SCD patients (FDA, 2017) . Among the many mechanisms of actions of HC administration in SCD patients, increase in fetal haemoglobin (HbF) is considered the most important in decreasing and/or preventing SCD-related manifestations, such as the frequency of vaso-occlusive crises, the need for blood transfusions, and protecting against primary stroke in patients with elevated Transcranial Doppler results (Charache et al, 1995; Ware, 2010; Paule et al, 2011) .
Hydroxycarbamide treatment ameliorates other aspects of SCD via other mechanisms of action, such as decreasing vascular occlusion by lowering numbers of circulating leucocytes and reticulocytes and decreasing the expression of adhesion molecules (Ware, 2010) . Studies also show that long-term HC administration results in a reduction in mortality and end organ disease, especially if HC is given at the maximum tolerable dose Voskaridou et al, 2010) .
Sickle cell retinopathy (SCR) is an ocular manifestation of SCD. Retinal ischaemia due to capillary closure is the basis for retinal manifestation of neo-vascularization (NVE), which, if left untreated, can lead to haemorrhaging, tractional retinal detachment, and blindness (De Melo, 2014) . SCR develops in up to 42% of SCD patients during the second decade of life and can be categorized as non-proliferative (NSR) or proliferative (PSR) based on the presence of NVE (Friberg et al, 1986) . Although HbSC disease is phenotypically milder than HbSS disease, the incidence of PSR is much higher in the HbSC population, reaching as high as 76% (Nagel et al, 2003) .
The National Heart, Lung, and Blood Institute (NHLBI) has issued guidelines stating that all sickle cell patients older research paper than 10 years of age should receive an annual ophthalmic examination for retinopathy, increased ocular pressure, and refraction errors (NHLBI, 2014) . Although there are no prospective studies that address the efficacy of HC therapy on decreasing the incidence of SCR, there is data suggesting that elevated HbF levels due to HC protects against SCR development in children with HbSS (Estepp et al, 2013) . After adjustment for HC treatment, HbSS children with HbF levels <15% had 7Á1 times the odds of developing SCR compared to subjects with HbF levels ≥15% (Estepp et al, 2013) .
Sickle cell retinopathy is known to increase with age, and despite high prevalence of retinopathy and HC use, no studies have examined HC use or HbF effects on adult SCD patients' risk of developing retinopathy. We report on a retrospective study of 300 SCD adults from the Montefiore Sickle Cell Center and Department of Ophthalmology and Visual Sciences in the Bronx, NY.
Methods
This study was a retrospective cross-sectional study approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board. Subjects were identified by cross-referencing the database of active SCD patients from the Montefiore Sickle Cell Center (age ≥ 18 years) with electronic medical record (EMR) data of patients evaluated at the Montefiore Ophthalmology Department during the 5 years of the study period (1 October 2012 to 30 November 2017). Patients were included in the study cohort if they had documented SCD of any genotype: HbSC, HbSS, or Sb Thalassaemia (including patients with Sb + and Sb 0 ). HbSb 0 thalassaemia patients were included in the HbSS group and HbSb + thalassaemia patients were included in the HbSC group. Patients were excluded from participation if they had sickle cell trait or had no dilated fundus examination recorded on the EMR. Three hundred patients met inclusion criteria for this study. Demographic data were collected from the EMR. Patient race was self-reported and was considered as not available when not provided. Sickle genotype was collected from the EMR and confirmed by an expert haematologist at the sickle cell centre.
Ophthalmological data was collected using patient EMRs. Data from the most recent evaluation was included in the study.
Each patient's EMR was searched for a positive history of comorbidities, such as splenic sequestration, priapism, leg ulcer, acute chest syndrome, gallstones, cholecystectomy or cholecystitis, stroke, osteonecrosis, and diabetes mellitus.
Medication history was assessed in the EMR to determine if the patient had ever been prescribed HC. If multiple doses were recorded, then the most recent dose (closest to the eye examination) was used to determine mg/kg. If a patient was no longer prescribed HC at the time of data collection, they were recorded as having previously taken the medication and included in the study as a HC user.
Lastly, haematological data was collected on all subjects. Haemoglobin, haematocrit, mean corpuscular volume, corpuscular haemoglobin concentration, platelet count, percentage of HbS, percentage of HbF, reticulocyte count, total bilirubin, white blood cell (WBC) count, and lactate dehydrogenase level were recorded. For inclusion in the study, the haematological data had to have been recorded within 12 months (before or after) of the patient's most recent eye examination.
Statistical analysis
Descriptive statistics are provided in terms of percentages, means, and standard deviations (SD). Comparisons between groups (e.g., between genotypes) were made by applying ttests for continuous outcome variables and Chi-square or Fisher exact tests for categorical outcome variables. A multivariable regression analysis was conducted to test significance of association between HbF level and retinopathy controlling for genotypes and gallstones. Determinations of optimal cutoff points were made based on the Youden index (= sensitivity + specificity À 1), which was obtained from receiver operating characteristic (ROC) analysis. Discriminatory power was assessed using area under curve (AUC) of ROC curves. Statistical significance was declared at P < 0Á05. All statistical analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Ophthalmic and haematological data for 300 SCD patients (53% female) was examined. There were 198 HbSS and Sb 0 thalassaemia (66%), 101 HbSC and Sb + thalassaemia patients (33Á7%), and one HbS/hereditary persistence of fetal haemoglobin (HPHF) ( Table SI) . Mean age for the entire cohort was 36Á4 years (range 18-71) ( Table I ). There were no age differences between the two genotype groups. Concerning race and ethnicity, 72% of patients self-identified as "Black" and 18% identified as "Hispanic", while 29 patients (9Á7%) did not respond (Table SI) . Within the HbSS cohort, subjects with retinopathy were significantly older than those without (39Á3 vs. 34Á4, P = 0Á0253, Table I ). These age differences were not present in the HbSC cohort between subjects with retinopathy and those without.
Out of all 300 patients, 94 (31Á3%) were diagnosed with sickle cell retinopathy. Of those patients, 20 (21%) had nonproliferative retinopathy, while 74 (79%) had PSR. Compared to HbSS patients, HbSC patients had significantly higher rates of retinopathy (44% vs. 25%, P = 0Á0013) and PSR (86% vs. 72%, P = 0Á0002, Table I ). This is consistent with what is already reported in the literature (Friberg et al, 1986; De Melo, 2014) .
Impact of hydoxycarbamide use and HbF level on retinopathy
Forty-seven percent of the total cohort were prescribed HC. In comparison to HbSC patients, HbSS patients had significantly higher rates of HC prescription (61% of HbSS patients vs. 19Á8% of HbSC patients, P < 0Á0001), as well as significantly higher levels of HbF (P < 0Á0001). Mean HC dose was 22 mg/kg in HbSS patients compared to 12Á9 mg/kg in HbSC patients.
Independent of HC use, there was an inverse relationship between retinopathy and HbF levels in HbSS patients (P = 0Á0373, Fig 1A, Table II) . Similarly, among the subgroup of HC users, those with retinopathy had significantly lower HbF levels compared to those without retinopathy (P = 0Á018, Fig 1B, Table II ). When we examined the HbSC cohort, we did not find a similar relationship between HbF level and retinopathy. Of note, HbSC patients had much lower levels of HbF whether or not they were prescribed HC (5Á5 vs. 12Á9, P < 0Á001). Only 20 subjects with HbSC were prescribed HC. One patient with HPHF was excluded from the HbF analysis.
All patients were divided into quartiles based on HbF levels (Q1 = 0Á1-1Á3%, Q2 = 1Á4-4Á9%, Q3 = 5-12Á7%, Q4 = 13-40%). In the HbSS/SB 0 cohort, 29% of patients with retinopathy had HbF levels <15%, whereas 15% of HbSS patients with retinopathy had HbF levels >15% (Table II) . This difference at an HbF level of 15% was found to be clinically significant (P = 0Á0467, Table II ). In the HbSC cohort, none of patients with HbF ≥15% had retinopathy, whereas 45% of the patients with HbF levels <15% had retinopathy. However, due to the small sample size, this difference was not significant, P = 0Á1224. The optimal HbF cut-off point for discriminating retinopathy with maximized Youden index was identified as 14Á87% for all HbSS patients ( Figure S1 ): sensitivity = 0Á84, specificity = 0Á32, AUC = 0Á59. HbSS subjects with a HbF less than this level are more likely to be positive for retinopathy (29Á0% vs. 15Á1%, P = 0Á047). In other words, an HbF of 15% appears to be the threshold where the risk of retinopathy is significantly reduced by approximately 50%. Overall, a multivariate logistic regression analysis showed that lower HbF level (<15% vs. ≥15%) remained significantly associated with retinopathy even after controlling for genotype and gallstones (adjusted odds ratio [OR] = 2Á50, 95% CI = (1Á11, 5Á76), P = 0Á027; Table III ).
Impact of hydroxycarbamide use and HbF level on proliferative retinopathy (PSR)
No similar relationship was found between HbF levels and PSR development for the subset of patients with PSR in both the HbSS and HbSC groups. Among HbSS patients with HbF <15%, 20Á7% had PSR compared to 11Á3% in those with HbF ≥15%. However, this trend did not reach significance (P = 0Á1302). None of the three HbSC patients with Percentages of retinopathy and PSR are significantly higher in SC patients compared to SS (P = 0.001 and P < 0.001, respectively). *Denotes significance, P < 0.05. HbF ≥15% had PSR, whereas 38 out of 98 (38Á8%) HbSC patients with HbF <15% had PSR (P = 0Á1721).
Clinical complications
Within each genotypic group, frequency of comorbidities was examined independently for patients with retinopathy and those without retinopathy. In the HbSS group, patients with retinopathy had a higher frequency of acute chest syndrome compared to those without retinopathy (P = 0Á08). In both the HbSS and HbSC group, there was a significantly higher frequency of gallstones/cholecystitis/cholecystectomy among patients with retinopathy compared to those with no retinopathy (P = 0Á0041 for HbSS and P = 0Á047 for HbSC, Table SII ). All other comorbidities examined were not significantly different in patients with or without retinopathy.
Haematological measurements
We found no correlations between haematological parameters and incidence of retinopathy, aside from HbF levels, as discussed above (data not shown).
Discussion
Our data suggest that an elevated HbF level is protective for retinopathy in a large urban cohort of adults with SCD patients. While the association between higher HbF and protection from retinopathy was statistically significant in patients with HbSS, there was a trend that did not reach significance in patients with HbSC. Our data confirms and expands upon previous observations of an inverse relationship between HbF level and incidence of retinopathy in children with HbSS (Estepp et al, 2013) . The incidence of retinopathy in our cohort was, as expected, higher in patients with HbSC (44/101, 44%) than in HbSS (50/198, 25%), and it was not as robustly correlated to HbF levels or HC use. A likely explanation for the lower prescription rate of HC in the HbSC group compared to the HbSS patients attributes to the fact that fewer patients with HbSC meet the current approved criteria for HC initiation (Luchtman-Jones et al, 2016; Nevitt et al, 2017) . Moreover, HbF increase in patients with HbSC is not as robust as in patients with HbSS (Charache et al, 1995; Luchtman-Jones et al, 2016; Nevitt et al, 2017) . Nevertheless, it is conceivable that HC could have the same beneficial effects in patients with HbSC in preventing retinopathy, provided an adequate dose is prescribed at an early enough age and higher HbF could be reached. Further prospective studies are warranted to explore this possibility. Interestingly, we were able to identify 15% as the HbF threshold above which retinopathy is approximately 50% less common. The presence of such a cut-off point above which SCD complications are ameliorated is corroborated by several studies that, both theoretically and clinically, have demonstrated a minimum level of HbF is needed to adequately suppress intracellular polymerization Estepp et al, 2017) . Therefore, it may be important, when treating patients with HbSS, to titrate hydroxycarbamide dose up in order to reach a minimum HbF level of 15%. This will help to reduce end organ disease, as recently suggested (Fitzhugh et al, 2017) .
Among the many clinical complications analysed in this study, only the presence of gallstones/cholecystitis/cholecystectomy was significantly associated with retinopathy in both HbSS and HbSC (albeit with a lower strength than in HbSS) groups. This finding could be interpreted as evidence that haemolysis plays a role in retinopathy development. On the other hand, we did not find such an association between retinopathy and those haematological parameters classically found to be increased in haemolysis, such as reticulocyte counts, indirect bilirubin, and low haemoglobin. Moreover, a multivariable regression analysis showed that gallstones were not independently associated with retinopathy. Future prospective data is needed to confirm our preliminary finding. SS, includes patients with HBSS and HBSB0. Association between fetal hemoglobin (HbF) level and the development of retinopathy in all patients and in those treated with hydroxycarbamide (HC). Mean HbF levels are significantly higher among SS patients without retinopathy (P = 0.018 for HC users, P = 0.037 for all patients). SS patients with HbF levels ≥ 15 have significantly lower rates of retinopathy than those with HbF levels <15 (P = 0.047). *Denotes significance, P < 0.05. In this study, we were not able to identify a relationship between PSR and HbF level, nor between PSR and HC use. This could be explained by the irreversibility of some forms of end organ damage, such as stroke and avascular necrosis. It is possible that earlier introduction of HC and/or a robust HbF induction will be able to prevent PSR, but even high HbF levels may not have the ability to reverse ischaemic damage once it has occurred.
There are several limitations to this study that need mentioning. First, as this was a retrospective, single institution study, we cannot exclude referral bias, which may have prioritized patients with HbSC. Additionally, the cross-sectional approach utilized in this study prevents us from being able to observe changes over time, specifically as they relate to the exact date of initiation of HC therapy or to HbF level fluctuations over time. It is conceivable that patients who started therapy earlier may have more benefits than patients who started HC later, presumably after the initial damage had already occurred. A parallel study of a subgroup of patients followed over a 3-year period is under preparation.
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